• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Rubraca

Graphic showing arrows missing the bullseye on a target
Pharma

ESMO: GSK's Zejula, pharma&'s Rubraca-Opdivo combo disappoint

Zejula didn't deliver a life extension benefit in first-line maintenance ovarian cancer, while Rubraca-Opdivo performed worse than Rubraca alone.
Angus Liu Sep 14, 2024 8:45am
Rubraca AstraZeneca

FDA sends CRL to Clovis in last-gasp bid for Rubraca nod

Jun 5, 2023 10:20am
Rubraca AstraZeneca

With Clovis in Chapter 11, Swiss firm buys up Rubraca for $70M

Apr 7, 2023 10:56am
mountain climb steep cliff climber struggle

Clovis reveals even more regulatory troubles for Rubraca

Feb 13, 2023 10:34am
Bankruptcy

Clovis finally throws in the towel, files for bankruptcy

Dec 12, 2022 12:23pm
Rubraca AstraZeneca

Loan default, Rubraca move inches Clovis closer to bankruptcy

Dec 5, 2022 10:25am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings